Jinghua Pharmaceutical announced that on September 8 and September 9, 2026, the closing price increase deviation value accumulated by more than 20% for two consecutive trading days, constituting abnormal stock fluctuations. According to the company's own investigation, there is no need to correct or supplement the information disclosed earlier. There have been no major changes in recent media reports, business conditions, or internal and external business environment; the company and controlling shareholders had no important matters that should be disclosed but not disclosed or are in the planning stage, and the controlling shareholders did not trade the company's shares during the period of abnormal fluctuations.

Jinghua Pharmaceutical announced that on September 8 and September 9, 2026, the closing price increase deviation value accumulated by more than 20% for two consecutive trading days, constituting abnormal stock fluctuations. According to the company's own investigation, there is no need to correct or supplement the information disclosed earlier. There have been no major changes in recent media reports, business conditions, or internal and external business environment; the company and controlling shareholders had no important matters that should be disclosed but not disclosed or are in the planning stage, and the controlling shareholders did not trade the company's shares during the period of abnormal fluctuations.